A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

  • Haydon, Andrew (Primary Chief Investigator (PCI))
  • Brooks, Christine (Project Manager)

Project: Research

Project Details

StatusActive
Effective start/end date4/01/23 → 3/01/25

Keywords

  • Clinical trial
  • mRNA-2752
  • Intratumoral Injection